<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app39.us.archive.org';v.server_ms=359;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml', '20160930215641')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930215641/https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930215641/https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930215641" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 21:56:41 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 21:56:41 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 21:56:41 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930215641*/https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-9862?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Radionuclide therapy for neuroendocrine malignancies.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Gulenchyn KY, Yao X, Asa SL, Singh S, Law C, Radionuclide Therapy for Neuroendocrine Tumours Expert Panel. Radionuclide therapy for neuroendocrine malignancies. Toronto (ON): Cancer Care Ontario (CCO); 2011 Aug 15. Various p.&amp;nbsp;(Evidence-based series; no. 12-13).&amp;nbsp; [90 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=101885&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Expert Panel and the Working Group offer the following recommendations based on the evidence reviewed:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Peptide receptor radionuclide therapy (PRRT) appears to be an acceptable option in adult patients with neuroendocrine cancer who are inoperable, have residual disease following surgery or other ablative therapy, or have metastases. PRRT is relatively safe and well tolerated with renal protection using lysine and arginine amino acid solution, especially for <sup>90</sup>Y-DOTALAN and <sup>177</sup>Lu-DOTATATE. However, renal function must be monitored. </li>
    <li>Treatment with PRRT in Ontario should be conducted as part of one or more randomized controlled trials (RCTs), or in large comparative clinical trials if an RCT is not feasible, under the authority of a Clinical Trials Agreement, to clarify the further effects of PRRT (for example, comparing <sup>177</sup>Lu-DOTATATE with sunitinib in an RCT). </li>
    <li><sup>131</sup>I-metaiodobenzylguanidine (<sup>131</sup>I-MIBG) may be effective for malignant neuroblastoma, paraganglioma, or pheochromocytoma, but there is insufficient evidence to suggest its efficacy for adult neuroendocrine carcinoma patients. However, the hematologic toxicity, severe infections, and secondary malignancies possible afterwards should be considered. </li>
</ul></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Neuroendocrine tumours (NETs)</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Assessment of Therapeutic Effectiveness"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Endocrinology"/>
      <fieldvalue value="Neurology"/>
      <fieldvalue value="Nuclear Medicine"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Radiation Oncology"/>
      <fieldvalue value="Radiology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>To evaluate what the effects of the eight commonly used and studied therapeutic radiopharmaceuticals described in Table 1 in the original guideline document are in patients with different types of neuroendocrine malignancies </li>
    <li>To evaluate which one of the eight therapeutic radiopharmaceuticals is most effective in improving clinical outcomes (i.e., tumour response, duration of tumour response, overall survival [OS] time/rate, progression-free survival [PFS] time/rate, biochemical response, and quality of life [QOL]) in patients with different types of neuroendocrine malignancies </li>
    <li>To evaluate what the toxicities are for each therapeutic radiopharmaceutical </li>
</ul>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Neuroendocrine cancer patients who are inoperable, have residual disease following surgery or other ablative therapy, or have metastases</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Peptide receptor radionuclide therapy (PRRT) </li>
    <li>Renal protection (lysine and arginine amino acid solution) </li>
    <li><sup>131</sup>I-metaiodobenzylguanidine (<sup>131</sup>I-MIBG) </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Tumour response </li>
    <li>Duration of tumour response </li>
    <li>Overall survival (OS) time/rate </li>
    <li>Progression-free survival (PFS) time/rate </li>
    <li>Biochemical response </li>
    <li>Quality of life (QOL) </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Literature Search Strategy</strong></p>
<p>A literature search was performed using MEDLINE and EMBASE through the Ovid search engine from January 1, 1998, to November 4, 2010. The search strategies are reported in Appendices 2 and 3 in the original guideline document. The following resources were checked for existing systematic reviews and practice guidelines: the Cochrane Library (to Issue 10, 2010) and the Standards and Guidelines Evidence Inventory of Cancer Guidelines (referred to below as the Inventory), which included guidelines identified in and/or published by the National Guideline Clearinghouse, the National Health and Medical Research Council (Australia), the New Zealand Guidelines Group, the Canadian Medical Association Infobase, the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the European Neuroendocrine Tumour Society, among others. Over 1100 English-language cancer control guidelines and standards released from 2003 through June 2010 were available in the Inventory when it was checked on October 18, 2010.</p>
<p><strong>Study Selection Criteria </strong></p>
<p><em>Inclusion Criteria</em></p>
<p>Articles were eligible for inclusion in this systematic review if they were:</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Full text reports published from January 1, 1998, to November 4, 2010. </li>
    <li>Clinical practice guidelines based on a systematic review, systematic reviews, randomized trials, prospective studies, or retrospective studies that reported on at least one clinical outcome. </li>
    <li>Prospective studies that had &amp;ge;30 patients. This number was considered the minimum number of subjects on which results could be reported with enough certainty (e.g., narrow enough 95% confidence intervals [CIs]) such that the data could be used in the formulation of recommendations. </li>
    <li>Retrospective studies that had &amp;ge;100 patients. This number is greater than that chosen for prospective studies because retrospective studies have a greater potential for bias and thus can be more difficult to interpret. </li>
    <li>Studies that included malignant neuroendocrine tumours (NET) patients who were inoperable or who had residual disease or metastases (patients could have been treated with prior systemic therapy). </li>
    <li>Studies that reported or compared the effects of any of eight therapeutic radiopharmaceuticals listed in Table 1 in the original guideline documents on any of the following clinical outcomes: complete response (CR), partial response (PR), minor response (MR), stable disease (SD), duration of response (DR), progression-free survival (PFS), overall survival (OS), biochemical response, quality of life (QOL), and toxicity. </li>
</ol>
<p><em>Exclusion Criteria</em></p>
<p>Articles were excluded if they met any of the following criteria:</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Were published in a language other than English </li>
    <li>Were non-systematic reviews, case reports, animal studies, letters, editorials or commentaries </li>
    <li>Recruited only patients with small-cell lung cancer (SCLC) </li>
    <li>Did not report any outcomes after radionuclide therapy (RT) in which systemic therapy was immediately followed RT </li>
</ol>
<p>The reference lists of the included articles were hand searched, and no further eligible papers were found.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Thirty-two articles were included in this systematic review.</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Synthesizing the Evidence</strong></p>
<p>If possible, meta-analyses of each trial outcome would be considered and conducted. The subgroup data with a denominator less than 10 were not reported because a sample size &amp;lt;10 is considered a case report. Any data for which denominators were &amp;lt;30 should be considered carefully because they usually have extremely large 95% confidence interval (CIs) and are unlikely to be statistically significant.</p>
<p>STATA 11.0 would be the statistical software for statistical calculation purposes and for producing figures. A two-sided significance level of &amp;alpha; = 0.05 was assumed.</p>
<p><strong>Study Quality</strong></p>
<p>The 24 included studies were assessed for quality (see Table 4 in the original guideline document), according to the Newcastle-Ottawa Scale used in non-randomized studies (NRS) method group workshops of the Cochrane Collaboration to illustrate issues in data extraction from primary NRS.</p>
<p><strong>Outcomes</strong></p>
<p>Meta-analyses of the trial results for tumour response rates on imaging and/or survival time/rates were not feasible. The various clinical centres differed in radionuclide therapy (RT) interventions, doses and treatment schema for the same intervention, patient characteristics, neuroendocrine tumour (NET) types, tumour status at baseline, and criteria for evaluating tumour response, making meaningful results from pooling impossible. Meta-analyses of outcomes for biochemical response, quality of life (QOL), and/or toxicity were also not feasible because of the differences in outcome assessment measurement and timing.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Methods</strong></p>
<p>The evidence-based series guidelines developed by the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO), use the methods of the Practice Guidelines Development Cycle. For this project, the core methodology used to develop the evidentiary base was the systematic review. Evidence was selected and reviewed by four members of the Radionuclide Therapy (RT) in Neuroendocrine Tumour (NET) Working Group and one methodologist of the PEBC. All data were audited by a second, and independent, person.</p>
<p>The systematic review is a convenient and up-to-date source of the best available evidence on RT for patients with malignant NETs.</p>
<p><strong>Radionuclide Therapy for Neuroendocrine Tumours Expert Panel Conference</strong></p>
<p>On March 4, 2011, the draft guideline was presented to members of the Radionuclide Therapy for Neuroendocrine Tumours Expert Panel. This guideline contained draft recommendations that had been crafted by the Working Group. There was no strong disagreement regarding these draft recommendations or evidentiary base. It was suggested that several recommendations be reworded into more action-oriented language, and that the order and classification of the recommendations and qualifying statements be changed somewhat to highlight the most important issues.</p>
<p>Some members of the Expert Panel did express concern with respect to the study selection criteria, specifically the sample size limits (i.e., &amp;ge;30 for prospective studies and &amp;ge;100 for retrospective studies). There was concern that retrospective studies with sample sizes of less than 100 may provide some valuable information not currently included.</p>
<p>Based on the Expert Panel's feedback, the Working Group members revised the recommendations in the guideline and the conclusion of the evidentiary base. As the time available for the completion of this guideline was limited, the Working Group decided to submit the updated draft to the Report Approval Panel (RAP) for review. At the same time, retrospective studies with sample size between 30 and 100 would be reviewed and the results provided in an appendix after RAP review.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Program in Evidence-based Care (PEBC) Director's Review</strong></p>
<p>Following the presentation of this evidence-based series (EBS) draft report for Expert Panel review, the report was reviewed and approved by the director of the PEBC, Dr. Melissa Brouwers, with expertise in methodologic issues.</p>
<p>In response to the RAP review feedback, all the raised points were revised by the Working Group.</p>
<p><strong>External Review by Ontario Clinicians and Other Experts</strong></p>
<p>The PEBC external review process is two pronged and includes a targeted peer review intended to obtain direct feedback on the draft report from a small number of specified content experts and a professional consultation intended to facilitate dissemination of the final guidance report to Ontario practitioners.</p>
<p>Following the review and discussion of Section 1: Guideline Recommendations and Section 2: Evidentiary Base of this EBS and the review and approval of the report by the PEBC RAP, the guideline authors circulated Sections 1 and 2 to external review participants for review and feedback.</p>
<p><em>Methods</em></p>
<p><span style=&quot;text-decoration: underline;&quot;>Targeted Peer Review</span></p>
<p>During the guideline development process, 11 targeted peer reviewers from the world considered to be clinical and/or methodological experts on the topic were identified by the guideline authors. Several weeks prior to completion of the draft report, the nominees were contacted by email and asked to serve as reviewers. Four reviewers agreed, and the draft report and a questionnaire were sent via email for their review. The questionnaire consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and whether the draft recommendations should be approved as a guideline. Written comments were invited. The questionnaire and draft document were sent out on April 29, 2011. Follow-up reminders were sent at two weeks and at four weeks. All the targeted peer reviewers were required to complete the conflict of interest form.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Professional Consultation</span></p>
<p>One hundred four potential participants were identified by the guideline authors. Feedback was obtained through a brief online survey of health care professionals who are the intended users of the guideline. Participants were asked to rate the overall quality of the guideline (Section 1 in the original guideline document) and whether they would use and/or recommend it. Written comments were invited. Participants were contacted by email and directed to the survey website where they were provided with access to the survey, the guideline recommendations (Section 1 in the original guideline document) and the evidentiary base (Section 2 in the original guideline document). The notification email was sent on May 3, 2011. Two follow-up reminders were sent on May 19 and May 31, 2011.</p>
<p><strong>Conclusion</strong></p>
<p>This EBS report reflects the integration of feedback obtained through the external review process with final approval given by the Radionuclide Therapy for Neuroendocrine Tumours Expert Panel and the Working Group.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations are supported by prospective trials.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Peptide Receptor Radionuclide Therapy (PRRT)</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Fifteen prospective single-arm articles and one prospective comparative study met the study selection criteria; of the nine published after 2005, all investigated the effects of <sup>90</sup>Y-DOTATOC, <sup>90</sup>Y-DOTATATE, or <sup>177</sup>Lu-DOTATATE. The total sample size was 1179. All the patient tumours showed a higher or the same uptake on octreoscan than on liver uptake before PRRT. All but one study reported the overall response rate as determined by three different imaging criteria in a variety of stage III-IV neuroendocrine tumour (NET) subgroups. Across all agents, overall response rates ranged from 5% to 75% in various tumour subgroups, with wide 95% confidence intervals (CI). </li>
    <li>Three studies were conducted in the same clinical centre to investigate the effects of <sup>111</sup>In-DTPAOC, <sup>90</sup>Y-DOTATOC, and <sup>177</sup>Lu-DOTATATE at different time periods. The median overall survival (OS) and progression-free survival (PFS) time was 37 and 14 months, respectively, for <sup>90</sup>Y-DOTATOC at five-year follow-up, and 46 and 33 months, respectively, for <sup>177</sup>Lu-DOTATATE at four years. The overall response rate was 18% (CI, 6% to 30%) for patients with progressive stage III-IV NET treated with <sup>111</sup>In-DTPAOC, 21% (CI, 11% to 31%) for patients with stage III-IV neuroendocrine gastroenteropancreatic tumours (GEP-NET) treated with <sup>90</sup>Y-DOTATOC, and 46% (CI, 40% to 52%) for patients with stage IV GEP-NET disease treated with <sup>177</sup>Lu-DOTATATE. </li>
    <li>Eight of the 16 articles reported survival outcomes, with six reporting median OS times ranging from 15 to 46 months for various stage III-IV NET subgroups. There was no significant difference in OS time between the intervention (14 patients treated with <sup>111</sup>In-DTPAOC and five patients treated with <sup>131</sup>I-metaiodobenzylguanidine [<sup>131</sup>I-MIBG]) and control arm in the unique comparative trial. </li>
</ul>
<p><strong><sup>131</sup>I-MIBG Therapy</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Six prospective single-arm, one retrospective comparative, and one retrospective single-arm study examining the effectiveness of <sup>131</sup>I-MIBG were eligible; the total sample size was 612. All the patients showed at least one lesion as positive on the <sup>123</sup>I-MIBG or <sup>131</sup>I-MIBG scintigraphy. The overall tumour response rate on imaging by various imaging criteria ranged from 32% to 75% for stage III-IV pediatric neuroblastoma patients with a median age of 2.0 to 6.6 years old (19-23) and was 26% for adult and stage III-IV NET patients (including 22 neuroblastomas, 10 pheochromocytomas, three paragangliomas, six medullary thyroid carcinomas, and four carcinoids) and 27% for patients with stage IV paraganglioma or pheochromocytoma. </li>
    <li>The Sywak et al. study was the unique comparative study for comparing standard therapies alone with standard therapies plus <sup>131</sup>I-MIBG in stage IV patients with midgut carcinoid. The OS rate was 63% (CI, 47% to 75%) in the intervention group and 47% (CI, 34% to 59%) in the control group at five years, without statistical significance (p=0.10). </li>
</ul></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Peptide Receptor Radionuclide Therapy (PRRT)</strong></p>
<p>Of the fifteen articles that reported on toxicity, 11 specified one of two criteria used for grading toxicity. Nausea and vomiting were common during therapy. The severe toxicities included the following: for <sup>111</sup>In-DTPAOC, 8% of patients developed myelodysplastic syndrome (MDS) and/or leukemia in one study; for <sup>90</sup>Y-DOTATOC, 0.9% to 3.4% of patients developed grade 4 renal toxicity in three studies, with 2% of patients developing MDS in one study; for <sup>90</sup>Y-DOTALAN, no severe toxicity was found in one study; for <sup>90</sup>Y-DOTATATE, 30% of patients developed grade 2 renal toxicity at two years in one study; and for <sup>177</sup>Lu-DOTATATE, 0.6% of patients developed hepatic insufficiency, 0.8% developed MDS, and 0.4% developed renal insufficiency in one study. For studies investigating the effects of <sup>90</sup>Y-DOTATOC, <sup>90</sup>Y-DOTATATE, and <sup>177</sup>Lu-DOTATATE, lysine and arginine amino acid solution was infused to protect kidney function.</p>
<p><strong><sup>131</sup>I-metaiodobenzylguanidine (<sup>131</sup>I-MIBG) Therapy</strong></p>
<p>Of seven studies reporting on toxicity, three used different criteria, and four studies did not specify the criteria for toxicity grading. Hematologic toxicities were the main severe side effects. Forty-three percent of patients had bone marrow replacement (BMR), and one patient developed secondary leukemia in one study. Five percent of patients in one study and 2% of patients in another study developed leukemia or MDS. In a retrospective study, five (4%) three- to five-year-old neuroblastoma patients developed secondary malignancies after <sup>131</sup>I-MIBG therapy either as part of first-line therapy or as salvage therapy for resistant or recurrent disease: one acute nonlymphoblastic leukemia at one and a half years, one chronic myelomonocytic leukemia at four years, one malignant schwannoma at seven years, one rhabdomyosarcoma at 14 years, and one angiomatoid malignant fibrous histiocytoma at 10 years after <sup>131</sup>I-MIBG. In a fifth study, 39% of patients needed autologous BMR, and 9% of patients died&amp;nbsp;where <sup>131</sup>I-MIBG was utilized as the first-line treatment. Forty-one percent of patients had grade 2-3 hematologic toxicities in a sixth study. After an accumulative dose of at least 63.3 gigabecquerels (GBq) <sup>131</sup>I-MIBG therapy, 4% of patients who did not have prior radiation or chemotherapy developed MDS and acute myeloid leukemia at two and five years, respectively, in the seventh study. In addition, 4% of patients in that same study developed acute respiratory distress syndrome, 4% developed bronchiolitis obliterans organizing pneumonia, and 2% had a pulmonary embolism.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>There is limited evidence, based on a historical comparison of studies from a single centre (see key evidence in the original guideline document), that <sup>177</sup>Lu-DOTATATE may be associated with greater overall survival (OS), progression-free survival (PFS), and overall response rate (defined as the sum of complete response, partial response, and minor response rates) compared with <sup>90</sup>Y-DOTATOC or <sup>111</sup>In-DTPAOC. Therefore, <sup>177</sup>Lu-DOTATATE would be an appropriate agent to include in the future clinical trials described in the original guideline document. </li>
    <li>Prior to the administration of therapy, the tumours from neuroendocrine tumour (NET) patients who are to receive peptide receptor radionuclide therapy (PRRT) or <sup>131</sup>I-metaiodobenzylguanidine (<sup>131</sup>I-MIBG) should demonstrate a positive uptake of the related diagnostic agent. </li>
    <li>A recommendation cannot be made for or against the use of PRRT in early-stage NET patients, as there is no relevant evidence. </li>
    <li>Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Quick Reference Guides/Physician Guides"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Gulenchyn KY, Yao X, Asa SL, Singh S, Law C, Radionuclide Therapy for Neuroendocrine Tumours Expert Panel. Radionuclide therapy for neuroendocrine malignancies. Toronto (ON): Cancer Care Ontario (CCO); 2011 Aug 15. Various p.&amp;nbsp;(Evidence-based series; no. 12-13).&amp;nbsp; [90 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2011 Aug 15"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="123" ordby="1230" id="448" name="Guideline Developer Comment" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.</p></div>"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Radionuclide Therapy for Neuroendocrine Tumours Expert Panel</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Expert Panel Members</em>: Dr. Leonard Kaizer, Medical Oncologist, Peel Regional Cancer Centre, Mississauga, Ontario; Dr. Travis Besanger, Head of Quality Assurance and Quality Control, Centre for Probe Development and Commercialization, Hamilton, Ontario; Dr. Daryl Gray, Surgical Oncologist, London Health Sciences Centre London, London, Ontario; Dr. Barry Ivo, Radiation Safety Office, University of Toronto, Toronto, Ontario; Dr. Eugene Leung, Nuclear Medicine Physician, Department of Nuclear Medicine, The Ottawa Hospital, Ottawa, Ontario; Dr. Robyn Pugash, Interventional Radiologist, University of Toronto, Toronto, Ontario; Dr. Robert (Robin) Reid, Associate Professor, Nuclear Medicine Physician, Victoria Hospital, London, Ontario; Dr. Rebecca Wong, Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario; Ms. Maureen Coleman, patient representative, Ontario</p>
<p><em>Working Group Members</em>: Dr. Karen Gulenchyn, Chief of Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, Ontario; Dr. Sylvia Asa, Pathologist-in-chief, University Health Network, Toronto, Ontario; Dr. Calvin Law, Associate Professor, Department of Surgery, University of Toronto, Toronto, Ontario; Dr. Simron Singh, Medical Oncologist, Neuroendocrine Clinic, Sunnybrook Health Sciences, Toronto, Ontario; Ms. Xiaomei Yao, Research Coordinator, Program in Evidence-based Care, Cancer Care Ontario, Hamilton, Ontario</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>In accordance with the Program in Evidence-based Care (PEBC) Conflict of Interest (COI) Policy, the guideline authors, Expert Panel members, and internal and targeted external reviewers were asked to disclose potential conflicts of interest. Three guideline authors declared they had no conflicts. Two others (S. Singh and C. Law) declared conflicts and reported receiving more than $5000 in a single year from consulting fees, honoraria, and/or other support from Novartis and Pfizer pharmaceutical companies. Both these authors also declared that they had received research grant support from Novartis.</p>
<p>For the Expert Panel, seven members declared they had no conflicts of interest, and two (T. Besanger and R. Reid) declared conflicts. TB reported receiving employment income from a previous employer, Molecular Insight Pharmaceuticals, a clinical developer of <sup>90</sup>Y-DOTATOC and <sup>131</sup>I-MIBG. RR reported receiving more than $5000 in a single year for travel expenses and research funding (now completed) from Novartis for his department for database development.</p>
<p>The PEBC Director (M. Brouwers) and the PEBC Assistant Director (H. Messersmith) declared that they had no COI.</p>
<p>For the targeted external reviewers, two declared they had no COI, and one (R. Lebtahi) declared conflicts. RL was the co-author in the European Neuroendocrine Tumour Society (ENETS) guideline, and he will be a principal investigator for a multicentre trial about <sup>111</sup>In-DTPAOC therapy in front of curative intent after complete resection of liver metastases in patients with neuroendocrine tumours (NETs) in France at the end of 2011 year.</p>
<p>The COI declared above did not disqualify any individuals from performing their designated role in the development of this guideline, in accordance with the PEBC COI Policy. To obtain a copy of the policy, please contact the PEBC office by email at ccopgi.mcmaster.ca.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=101885&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=101885&quot; title=&quot;Care Ontario Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Radionuclide therapy for neuroendocrine malignancies. Summary. Toronto (ON): Cancer Care Ontario (CCO). 2011 Aug 15. 8 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=101887&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>Cancer Care Ontario (CCO) Web site</a>. </li>
    <li>Program in Evidence-Based Care (PEBC) handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Electronic copies: Available in PDF from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=50876&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>CCO Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on September 6, 2013.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the <a href=&quot;http://www.cancercare.on.ca/ontariocancernews/copyright.html&quot; title=&quot;CCO Web site&quot;>Copyright and Disclaimer Statements</a> posted at the Program in Evidence-based Care section of the Cancer Care Ontario Web site.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 21:56:41 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 01:07:47 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 143.433 (3)
  esindex: 0.009
  captures_list: 163.929
  CDXLines.iter: 15.115 (3)
  PetaboxLoader3.datanode: 147.752 (4)
  exclusion.robots: 0.383
  exclusion.robots.policy: 0.363
  RedisCDXSource: 1.538
  PetaboxLoader3.resolve: 91.763
  load_resource: 151.683
-->